Eagle Pharmaceuticals (NYSE: EGRX) — Perfil da empresa, notícias e dados financeiros
Eagle Pharmaceuticals develops critical care and oncology products, optimizing existing formulations for better patient outcomes.
Eagle Pharmaceuticals
Eagle Pharmaceuticals (NASDAQ:EGRX) is a specialty pharmaceutical company focused on developing and commercializing critical care and oncology products. Using its proprietary technology, Eagle works to improve existing formulations, enhancing the effectiveness and accessibility of medicines for patients in need. The company's portfolio includes innovative treatments for acute pain, cancer support care, and critical care products. Eagle Pharmaceuticals is dedicated to making its pharmaceuticals more effective while maintaining safety and convenience for patients. Its objectives include continuing to expand its product line through both in-house development and strategic partnerships, aiming to address unmet medical needs in the healthcare sector.
Resumo
Operações
Produtos e/ou serviços de Eagle Pharmaceuticals
- Bendeka (bendamustine hydrochloride injection), a treatment for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma.
- Ryanodex (dantrolene sodium) for the treatment of malignant hyperthermia, a life-threatening clinical syndrome.
- Pemfexy (pemetrexed injection), a branded alternative to Alimta for the treatment of non-squamous non-small cell lung cancer and malignant pleural mesothelioma.
- Vasopressin Injection USP for increasing blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
- BELRAPZO (bendamustine hydrochloride injection), another formulation of bendamustine for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma treatment.
- Fulvestrant Injection, a generic version for the treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women.
equipe executiva do Eagle Pharmaceuticals
- Mr. Michael GravesCEO & Chairman
- Mr. Christopher Krawtschuk CPACFO and Principal Financial & Accounting Officer
- Mr. Daniel O'ConnorExecutive VP, Chief Strategy Officer & Head of Corporate Development
- Dr. Valentin R. Curt M.D.Senior Vice President of Clinical Drug Development
- Ms. Debra Marie HussainSenior VP & Head of Commercial
Principais indicadores financeiros
Resultados divulgados pela Eagle Pharmaceuticals, em USD.
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 316,6 mi | 81 mi | 35,6 mi | |
| 171,5 mi | 2,8 mi | -8,6 mi | |
| 187,8 mi | 33 mi | 12 mi | |
| 195,9 mi | 21,8 mi | 14,3 mi |